Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).

Laura L HammittDean QuinnEwa JanczewskaFrancisco J PasquelRichard TytusK Rajender ReddyKatia AbarcaIlsiyar M KhaertynovaRon DaganJennifer McCauleyKyeongmi CheonAlison PedleyTina SterlingGretchen TammsLuwy K MuseyUlrike K Buchwald

Published in: Open forum infectious diseases (2021)

NCT03547167 and EudraCT 2017-004915-38.

Keyphrases

open label
cancer therapy
clinical trial
randomized controlled trial
double blind
placebo controlled